MVT-602: Side Effects

Safety Overview#

MVT-602 has been evaluated in Phase 1 and Phase 2a clinical trials in healthy premenopausal women. Across both studies, MVT-602 was described as generally well tolerated with no serious adverse events reported. The safety database is limited to small numbers of healthy volunteers with single-dose exposure.

Reported Side Effects#

Detailed adverse event frequency data from MVT-602 clinical trials have not been comprehensively published. The available data indicate:

• Treatment was "generally well tolerated" across both Phase 1 and Phase 2a studies
• No serious adverse events were reported
• No dose-limiting toxicities were identified

Based on the kisspeptin pharmacology and experience with kisspeptin-54 in IVF triggering, potential side effects include:

• Injection site reactions: Expected with subcutaneous peptide administration
• Abdominal discomfort: Related to ovarian activity following LH surge
• Headache: Observed with reproductive hormone changes

OHSS Risk Comparison#

The key safety advantage of MVT-602 over hCG triggering relates to ovarian hyperstimulation syndrome (OHSS). Because MVT-602 works through the self-limiting kisspeptin-GnRH-LH pathway rather than directly activating LH receptors with a long-acting agent, the OHSS risk is expected to be substantially lower:

• hCG triggers: OHSS rates of 3-8% in general IVF populations, up to 20-30% in high-risk patients (PCOS)
• GnRH agonist triggers: Very low OHSS rates but risk of inadequate oocyte maturation
• Kisspeptin-54 triggers: Zero OHSS cases in published research (Professor Dhillo's group)
• MVT-602: Expected low OHSS risk based on mechanism; not yet quantified in clinical data

Contraindications#

As an investigational compound, formal contraindications have not been established. Based on mechanism and general principles:

• Known or suspected pregnancy
• Active hormone-dependent malignancies
• Undiagnosed abnormal uterine bleeding

Drug Interactions#

MVT-602's mechanism requires an intact hypothalamic-pituitary-gonadal axis:

• GnRH antagonists (cetrorelix, ganirelix): Standard in IVF protocols to prevent premature ovulation. Timing of MVT-602 relative to last GnRH antagonist dose may affect the LH surge amplitude
• GnRH agonists (leuprolide): Concurrent use could produce excessive gonadotropin release or pituitary desensitization
• Gonadotropins (FSH/LH): The intended clinical context; not an adverse interaction

Safety Profile Context#

MVT-602 belongs to the Reproductive category of research peptides. Understanding the side effect profile of MVT-602 is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of MVT-602. Side effect severity and frequency are based on available clinical data.

Injection site reactions#

Severity: mild | Frequency: common

Mild injection site reactions (pain, erythema) are expected with subcutaneous peptide administration, consistent with other injectable reproductive peptides.

Headache#

Severity: mild | Frequency: uncommon

Headache has been reported with kisspeptin-based compounds, likely related to the endocrine changes (LH/FSH surge) triggered by KISS1R activation.

Contraindications#

The following contraindications have been identified for MVT-602 based on available research and pharmacological considerations:

• Not established -- MVT-602 is investigational and formal contraindications have not been defined through regulatory review
• Pregnancy (kisspeptin signaling modulates reproductive axis; effects on early pregnancy unknown)
• Known KISS1R-related conditions where additional kisspeptin signaling stimulation may be inappropriate

Individuals with any of these conditions should not use MVT-602 without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for MVT-602:

• GnRH agonists and antagonists may interfere with MVT-602 mechanism since MVT-602 works through the endogenous GnRH pathway. GnRH antagonist protocols (standard in many IVF regimens) would need specific timing considerations.
• Gonadotropin preparations (FSH/LH) used during ovarian stimulation represent the intended clinical context, not a contraindicated interaction.

Drug interaction studies for MVT-602 remain limited. Researchers should exercise caution when combining MVT-602 with other compounds and consult relevant pharmacological references.

Related Reading#

• MVT-602 overview and research guide
• MVT-602 dosing protocols
• MVT-602 risks and legal status